TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35236763

Group type: EXPERIMENTAL
Intervention: Lung volume recruitment (LVR) twice daily for 2 years
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 66
Study: 32798224

Group type: EXPERIMENTAL
Intervention: fIPV
Number of subjects: 250

Group type: COMPARATOR
Intervention: IPV
Number of subjects: 250
Study: 35140347

Group type: EXPERIMENTAL
Intervention: 10 mg of the µ‐opioid agonist morphine sulfate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 33771357

Group type: EXPERIMENTAL
Intervention: Titrated positive end-expiratory pressure (PEEP)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Fixed positive end-expiratory pressure (PEEP) of 5 cmH2O
Number of subjects: 82
Study: 35974938

Group type: EXPERIMENTAL
Intervention: Levetiracetam (1000 mg)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sodium valproate (1000 mg)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lamotrigine (250 mg)
Number of subjects: 102
Study: 33689731

Group type: EXPERIMENTAL
Intervention: Midodrine (5 mg TDS, up-titrated to 30 mg/day after one week)
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.05 mg BD, up-titrated to 0.2 mg/day after one week)
Number of subjects: 1375

Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Number of subjects: 1375
Study: 32930386

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (n = 2029)
Number of subjects: 4052

Group type: COMPARATOR
Intervention: Control arm without intervention (n = 2023)
Number of subjects: 4052

Group type: EXPERIMENTAL
Intervention: Statistical modeling
Number of subjects: 4052
Study: 32385678

Group type: EXPERIMENTAL
Intervention: Enhanced PrEP (enPrEP) adherence support including peer navigation, in-person/online support groups, and SMS messages
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard of care (sPrEP)
Number of subjects: 204
Study: 33307900

Group type: EXPERIMENTAL
Intervention: SB-ACT program
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: DOT-only for 6-8 weeks
Number of subjects: 430

Group type: COMPARATOR
Intervention: Asthma education (AE) attention control
Number of subjects: 430
Study: 32179023

Group type: EXPERIMENTAL
Intervention: Multimodal intervention to improve vaccination rates including designation of an immunization champion, purchasing vaccines, guidance on storage and management, routine identification of eligible patients, standing orders for vaccination, and vaccine administration.
Number of subjects: 40000
Study: 35504988

Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nomogram incorporating marital status, age, grade, tumor size, surgery of primary site, surgery of lymph node and metastatic
Number of subjects: 0
Study: 32414386

Group type: EXPERIMENTAL
Intervention: Hemoadsorption (HA) device
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (without HA device)
Number of subjects: 18
Study: 33772971

Group type: EXPERIMENTAL
Intervention: MDD+ smokers
Number of subjects: 1854

Group type: COMPARATOR
Intervention: MDD‐ smokers
Number of subjects: 1854
Study: 33060837

Group type: EXPERIMENTAL
Intervention: Convolutional neural network (CNN) based computer-aided detection (CAD) system using eDenseYOLO.
Number of subjects: 9792
Study: 33594386

Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine hydrochloride film (APL‐130277, Kynmobi) administered up to 5 times a day
Number of subjects: 0
Study: 32866927

Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 2500
Study: 35316458

Group type: EXPERIMENTAL
Intervention: Facing History and Ourselves intervention group
Number of subjects: 694

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 694
Study: 32187315

Group type: EXPERIMENTAL
Intervention: Home visits from nurses in addition to outpatient consultations
Number of subjects: 29

Group type: COMPARATOR
Intervention: Outpatient consultations only
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 35850436

Group type: EXPERIMENTAL
Intervention: Lithothamnion (100 mg/kg bw PO BID) for 7 days before oligofructose intake (10 g/kg PO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 12
Study: 33112408

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 400 Units at 12-week intervals
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA in extension cycles 1, 2, and 3
Number of subjects: 465

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Number of subjects: 465
Study: 35872954

Group type: EXPERIMENTAL
Intervention: Overall oral care (observation group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Basic oral care (control group)
Number of subjects: 70
Study: 33861701

Group type: EXPERIMENTAL
Intervention: Novel automatic initialization using a neural network trained to detect anatomical landmarks on simulated X-rays.
Number of subjects: 0
Study: 32903140

Group type: EXPERIMENTAL
Intervention: Stage 1 tumors
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Stage 2 tumors in patients < 18 months
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Stage 2 tumors in patients ≥ 18 months
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: 1p loss in patients < 18 months
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: 11q loss in patients ≥ 18 months
Number of subjects: 317
Study: 34692725

Group type: EXPERIMENTAL
Intervention: Silybin-phospholipids complex (303 mg), 10 μg of vitamin D, and 15 mg of vitamin E twice a day for 6 months (wild type treated group)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (NAFLD wild type controls)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Silybin-phospholipids complex (303 mg), 10 μg of vitamin D, and 15 mg of vitamin E twice a day for 6 months (mutated treated group)
Number of subjects: 92
Study: 33925277

Group type: EXPERIMENTAL
Intervention: Circuit weight-interval training (CWIT) for 12 weeks, 2 sessions of 40 minutes per week
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (continued sedentary behavior)
Number of subjects: 27
Study: 34181714

Group type: EXPERIMENTAL
Intervention: cPass neutralization antibody assay
Number of subjects: 316

Group type: COMPARATOR
Intervention: Commercial serology assays (Abbott, Euroimmun, Siemens)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Commercial serology assays (Abbott)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Commercial serology assays (Euroimmun)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Commercial serology assays (Siemens)
Number of subjects: 316
Study: 32118260

Group type: EXPERIMENTAL
Intervention: eHealth system
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Self-reported daily abstinence
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 12S-ABS and HC-ABS patients
Number of subjects: 115
Study: 35962654

Group type: EXPERIMENTAL
Intervention: Manual breastmilk expression (ME) using Marmet technique
Number of subjects: 170

Group type: COMPARATOR
Intervention: Breast pump milk expression (PE) using pigeon manual breast pump
Number of subjects: 170
Study: 33836800

Group type: EXPERIMENTAL
Intervention: ChemoRadiation and Immunotherapy (CRIO) with durvalumab (anti-PD-L1 checkpoint inhibitor)
Number of subjects: 15
Study: 35469779

Group type: EXPERIMENTAL
Intervention: Auditory, tactile, visual, and vestibular (ATVV) intervention
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Auditory, tactile, visual, and vestibular with odor from a baby lotion (ATVVO)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Attention control (AC) group
Number of subjects: 102
Study: 33342580

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention in addition to usual care
Number of subjects: 224

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 224
Study: 33093598

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Levodopa-entacapone-carbidopa intestinal gel (LECIG)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Entacapone with LCIG
Number of subjects: 11
Study: 35916398

Group type: EXPERIMENTAL
Intervention: Homebound Elderly People Psychotherapeutic Intervention (HEPPI)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 51
Study: 33989106

Group type: EXPERIMENTAL
Intervention: Standard dose (20 µg) of recombinant hepatitis B vaccine
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: High dose (60 µg) of recombinant hepatitis B vaccine
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: CHAID analysis
Number of subjects: 284
Study: 32951731

Group type: EXPERIMENTAL
Intervention: Intravenous Gamma Globulin (IVIG)
Number of subjects: 0
Study: 33612830

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 32441833

Group type: EXPERIMENTAL
Intervention: L-arginine (5 g)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tadalafil (5 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined L-arginine (5 g) with tadalafil (5 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 33646930

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 75 mg daily
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 32808018

Group type: EXPERIMENTAL
Intervention: Gold marker matching in the surrounding tissue of the prostate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bone matching
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Gold marker matching
Number of subjects: 38
Study: 36450546

Group type: EXPERIMENTAL
Intervention: Chronic Remote Ischemic Conditioning (CRIC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 33131199

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 53
Study: 33184642

Group type: EXPERIMENTAL
Intervention: 2000 IU/d vitamin D3
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 4000 IU/d vitamin D3
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 33405453

Group type: EXPERIMENTAL
Intervention: Autogenous dentin graft (Group D)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mixture of PRF and autogenous dentin graft (Group DP)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 9
Study: 32346743

Group type: EXPERIMENTAL
Intervention: Physical therapy with motor imagery (MI) principles
Number of subjects: 24

Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 24
Study: 35312850

Group type: EXPERIMENTAL
Intervention: EA model
Number of subjects: 0

Group type: COMPARATOR
Intervention: DB model
Number of subjects: 0
Study: 34110478

Group type: EXPERIMENTAL
Intervention: HM laparoscopic trainer
Number of subjects: 26

Group type: COMPARATOR
Intervention: KS trainer
Number of subjects: 26
Study: 32826836

Group type: EXPERIMENTAL
Intervention: Table position (T)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Forearm position with head close to provider's elbow (P)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Forearm position with head close to provider's palm (D)
Number of subjects: 52
Study: 34564686

Group type: EXPERIMENTAL
Intervention: Topical dexamethasone 2mg/5ml
Number of subjects: 32

Group type: COMPARATOR
Intervention: Topical cyclosporine 100mg/ml
Number of subjects: 32
Study: 35368605

Group type: EXPERIMENTAL
Intervention: Sertraline treatment
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo nonresponders
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo responders
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 193
Study: 37821187

Group type: EXPERIMENTAL
Intervention: PCI with everolimus-eluting stent
Number of subjects: 880

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Both PCI and CABG
Number of subjects: 880
Study: 32462277

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide mixed with lidocaine HCl
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcium hydroxide mixed with saline
Number of subjects: 60
Study: 32353115

Group type: EXPERIMENTAL
Intervention: Cosyntropin (70 μg/hour for 2.5 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 0
Study: 35943903

Group type: EXPERIMENTAL
Intervention: Online peer support intervention based on acceptance and commitment therapy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 107
Study: 36445895

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Relapse Prevention (RP)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Assessment-Only (AO)
Number of subjects: 101
Study: 34481070

Group type: EXPERIMENTAL
Intervention: Computer-generated smoking cessation pharmacotherapy recommendation algorithm integrated into HIV primary care
Number of subjects: 600

Group type: COMPARATOR
Intervention: Enhanced usual care condition
Number of subjects: 600
Study: 35258750

Group type: EXPERIMENTAL
Intervention: Rhythmic Skeletal Muscle Tension (RSMT) at 1 contractions per minute (cpm)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Rhythmic Skeletal Muscle Tension (RSMT) at 6 contractions per minute (cpm)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Rhythmic Skeletal Muscle Tension (RSMT) at 12 contractions per minute (cpm)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Rhythmic Skeletal Muscle Tension (RSMT) at 1 and 6 cpm
Number of subjects: 49
Study: 32073111

Group type: EXPERIMENTAL
Intervention: Ionically crosslinked polyisoprene elastomers with varying molecular weight and carboxy group content
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher molecular weight PI elastomers
Number of subjects: 0
Study: 36332361

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) with paracetamol
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Artesunate‐amodiaquine (ASAQ)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Pyronaridine‐artesunate (PA)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Favipiravir plus nitazoxanide (FPV + NTZ)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Sofosbuvir‐daclatasvir (SOF‐DCV)
Number of subjects: 186
Study: 33176071

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 71
Study: 35527651

Group type: EXPERIMENTAL
Intervention: Stimunex® gocce (food supplement) given daily for 4 months
Number of subjects: 298

Group type: COMPARATOR
Intervention: Standard therapy for respiratory infections (Control group)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Stimunex® gocce (food supplement)
Number of subjects: 298
Study: 32134279

Group type: EXPERIMENTAL
Intervention: Acting with awareness (AWA)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Negative affect through AWA
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Negative affect through suppression
Number of subjects: 210
Study: 32740442

Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SCB)
Number of subjects: 642
Study: 32621557

Group type: EXPERIMENTAL
Intervention: Glycated haemoglobin (HbA1c) levels above 7%
Number of subjects: 14656

Group type: EXPERIMENTAL
Intervention: Glycated haemoglobin (HbA1c) levels below 7%
Number of subjects: 14656
Study: 35938327

Group type: EXPERIMENTAL
Intervention: Staged acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 60
Study: 33658030

Group type: EXPERIMENTAL
Intervention: Malocclusion severity
Number of subjects: 255
Study: 35410930

Group type: EXPERIMENTAL
Intervention: Reusable catheters replaced every 2 weeks and cleaning solution replaced every 24 hours
Number of subjects: 456

Group type: COMPARATOR
Intervention: Single use catheters
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Reusable catheters
Number of subjects: 456
Study: 33843667

Group type: EXPERIMENTAL
Intervention: Nattokinase 2,000 fibrinolytic units
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 34226231

Group type: EXPERIMENTAL
Intervention: Daily patient contact
Number of subjects: 1874

Group type: EXPERIMENTAL
Intervention: Direct contact with COVID-19 patients
Number of subjects: 1874

Group type: EXPERIMENTAL
Intervention: Working in COVID-19 units
Number of subjects: 1874

Group type: EXPERIMENTAL
Intervention: Contact in patient rooms
Number of subjects: 1874

Group type: EXPERIMENTAL
Intervention: Contact in reception areas
Number of subjects: 1874

Group type: EXPERIMENTAL
Intervention: Household contact with suspected or proven SARS-CoV-2 infection
Number of subjects: 1874

Group type: EXPERIMENTAL
Intervention: Household contact with proven SARS-CoV-2 infection
Number of subjects: 1874

Group type: EXPERIMENTAL
Intervention: Consistent mask use on public transportation
Number of subjects: 1874
Study: 35789639

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 144

Group type: COMPARATOR
Intervention: Dynamic neuromuscular stabilization (DNS) exercise
Number of subjects: 144
Study: 33743737

Group type: EXPERIMENTAL
Intervention: D-galactose supplementation
Number of subjects: 9
Study: 32856272

Group type: EXPERIMENTAL
Intervention: Single RAS blocker therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Dual RAS blocker therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Both single and dual RAS blocker therapy
Number of subjects: 112
Study: 70711958

Group type: EXPERIMENTAL
Intervention: Arginaid formula (arginine enhanced diet, ISOCAL<sup>R</sup>) - 3 packs/day for 2 days before surgery and on postoperative days 4 to 9
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (no Arginaid)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Arginaid formula (arginine enhanced diet, ISOCAL<sup>R</sup>)
Number of subjects: 330
Study: 36129749

Group type: EXPERIMENTAL
Intervention: mHealth app (Mobile for Mothers)
Number of subjects: 740
Study: 34519400

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist (GLP-1RA) therapy
Number of subjects: 0
Study: 32118792

Group type: EXPERIMENTAL
Intervention: Intrusive force of 300g applied for 1 week (t=1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intrusive force of 300g applied for 4 weeks (t=4)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intrusive force of 300g applied for 8 weeks (t=8)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intrusive force of 300g applied for 12 weeks (t=12)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (t=0) - teeth extracted without orthodontic treatment
Number of subjects: 15
Study: 35195015

Group type: EXPERIMENTAL
Intervention: VERB intervention (educational materials, brief motivational interview, pillbox, primary care engagement letter, pharmacy resources, and 45 days of informational and reminder text messages)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: VERB intervention
Number of subjects: 206

Group type: COMPARATOR
Intervention: Education arm (received a hypertension pamphlet)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Education arm
Number of subjects: 206
Study: 34106135

Group type: EXPERIMENTAL
Intervention: Changing significance level from α = 0.05 to α = 0.005 in cross-sectional studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changing significance level from α = 0.05 to α = 0.005 in comparative studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost implications of changing significance level
Number of subjects: 0
Study: 32758278

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34240265

Group type: EXPERIMENTAL
Intervention: Resistance training with nutritional supplementation (Fortifit)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Resistance training without nutritional supplementation
Number of subjects: 95

Group type: COMPARATOR
Intervention: Cognitive training (control for socialisation)
Number of subjects: 95
Study: 33914319

Group type: EXPERIMENTAL
Intervention: TachoSil (collagen patches coated with human coagulation factors)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (side without TachoSil applied)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 35818060

Group type: EXPERIMENTAL
Intervention: Dynamic medial patellofemoral ligament reconstruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static medial patellofemoral ligament reconstruction
Number of subjects: 0
Study: 34129024

Group type: EXPERIMENTAL
Intervention: Peer-to-peer (P2P) support
Number of subjects: 448

Group type: COMPARATOR
Intervention: Standard community services (SCS)
Number of subjects: 448
Study: 32891289

Group type: EXPERIMENTAL
Intervention: Breathing exercise for six days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 60
Study: 35312016

Group type: EXPERIMENTAL
Intervention: Quartz diorite
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rhomb porphyry
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control dust (lactose)
Number of subjects: 24
Study: 33970657

Group type: EXPERIMENTAL
Intervention: Dynamic therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cognitive therapy
Number of subjects: 100
Study: 32442300

Group type: EXPERIMENTAL
Intervention: Metaphase cytogenetic abnormalities, PCPro, FISH gain 1q
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Risk scoring system based on R-ISS and age
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Metaphase cytogenetics
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: PCPro and FISH gain 1q
Number of subjects: 483